← Browse by Condition
Medical Condition

obese adults

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1

ClinicalMetric tracks all active clinical trials for obese adults sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — obese adults Clinical Trials

How many clinical trials are currently recruiting for obese adults?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for obese adults, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for obese adults?
obese adults research spans Phase 1 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a obese adults clinical trial?
Eligibility criteria for obese adults trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Top Sponsors
Viking Therapeutics, Inc. 1 trial
IRCCS Azienda Ospedaliero-Universitaria di Bologna 1 trial
Leeds Beckett University 1 trial

Recruiting Clinical Trials

NCT07846033 Phase 1
Recruiting
A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities
Enrollment
56 pts
Location
United States
Sponsor
Viking Therapeutics, Inc.
View Trial →
NCT07666425
Recruiting
ASSESSMENT OF THE NATURAL HISTORY AND PROGNOSTIC FACTORS OF THERAPEUTIC RESPONSE IN SUB-PHENOTYPES OF PATIENTS WITH OBESITY: THE BOLOBE STUDY
Enrollment
10,000 pts
Location
Italy
Sponsor
IRCCS Azienda Ospedaliero-Univ...
View Trial →
NCT07073781
Recruiting
Probiotics, Cognition and Metabolic Health in Young Adults With Overweight or Obesity
Enrollment
70 pts
Location
United Kingdom
Sponsor
Leeds Beckett University
View Trial →

Related Conditions

overweight obesity (1) impaired glucose tolerance prediabetes (1) prediabetes insulin resistance impaired glucose tolerance (1) overweight bmi gt 25 (1) cognitive dysfunction (1) neurovascular coupling mechanism and cognitive function (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology